40+ Testosterone Decline: NAD+, Leydig Cell Senescence, and the Longevity Axis

Two parallel age-related processes converge to reduce testosterone output in men over 40. First, hypothalamic GnRH neurons undergo progressive loss of pulse amplitude and interpulse interval regularity — a process driven partly by reduced kisspeptin signaling (the primary GnRH secretagogue), reduced sensitivity to gonadal steroid feedback, and accumulating oxidative damage to hypothalamic neurons. Longitudinal studies show that LH pulse amplitude in men over 65 is approximately 35% lower than in young adult controls, reducing the maximal Leydig cell stimulus.

Second, Leydig cell number declines with age — human autopsy studies demonstrate a 44% reduction in Leydig cell count between ages 20 and 80, with surviving cells showing reduced StAR expression and mitochondrial membrane potential. This cellular senescence is not simply passive attrition; senescent Leydig cells acquire a senescence-associated secretory phenotype (SASP) with elevated IL-6 and TNF-α, which further suppresses local steroidogenesis through cytokine-mediated CYP11A1 and StAR inhibition. The combination of reduced central LH drive and reduced peripheral Leydig cell capacity creates a compounding deficit that neither pathway-specific intervention alone fully addresses.

Nicotinamide adenine dinucleotide (NAD+) is the universal electron acceptor in cellular metabolism and an obligate substrate for sirtuin deacylases (SIRT1–7). The Verdin lab demonstrated that NAD+ concentrations in multiple mammalian tissues fall approximately 50% between young adulthood and midlife, with continued decline thereafter. The primary mechanism is increased activity of CD38 (a NAD+ glycohydrolase), increased PARP activity from accumulating DNA damage, and reduced expression of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway.

SIRT1 and SIRT3 are the most directly relevant sirtuins for testosterone-relevant physiology. SIRT1 deacetylates PGC-1α, activating it and driving transcription of mitochondrial biogenesis genes (NRF1, TFAM, and electron transport chain subunits). SIRT3 deacetylates and activates electron transport chain Complex I subunits and MnSOD (mitochondrial superoxide dismutase). Both effects converge on Leydig cell mitochondrial function — the organelle that houses StAR-dependent cholesterol transport and CYP11A1 activity. NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) both enter the NAD+ salvage pathway: NR is phosphorylated to NMN by NRK1/2, and NMN is adenylated to NAD+ by NMNAT. Human RCTs with NR at 300–1000 mg/day demonstrate 40–60% increases in blood NAD+ metabolite concentrations.

SHBG increases approximately 1.2 nmol/L per decade in men, driven by multiple age-related factors: declining insulin sensitivity (insulin suppresses SHBG expression in hepatocytes), declining free androgen levels (androgens suppress SHBG transcription), and hepatic changes in glycosylation patterns that increase SHBG half-life. By age 60, SHBG is typically 40–60% above young adult levels, compressing free testosterone to fractions that can be clinically significant even with total T in the normal range.

Eurycoma longifolia's eurycomanone has the best-characterized mechanism for SHBG competition among botanical compounds. Eurycomanone's steroidal backbone allows it to compete for SHBG binding sites with high affinity, displacing bound testosterone and increasing the free fraction. Unlike pharmacological aromatase inhibitors (anastrozole, letrozole), which reduce SHBG by lowering estrogen (which upregulates SHBG), eurycomanone acts through direct binding competition — a complementary and additive mechanism. In aging men where SHBG elevation is multi-factorial, combining direct SHBG competition (eurycomanone) with androgen-mediated SHBG suppression (via testosterone restoration) and insulin-sensitizing interventions (exercise, berberine) addresses the multiple upstream drivers simultaneously.

Clinical evidence for NAD+ precursor supplementation in aging men has expanded substantially since 2018. NR supplementation (300–500 mg/day) in multiple double-blind RCTs demonstrates 40–60% increases in whole-blood NAD+ and NAAD (a sensitive marker of NR flux through the pathway). NMN supplementation (250–500 mg/day) shows comparable blood NAD+ increases with slightly higher bioavailability in some comparative studies. Neither compound has been tested in an adequately powered RCT with testosterone as a primary outcome — this is an important gap.

However, mechanistic pathway analysis strongly supports the relevance: aging men with low NAD+ show impaired Leydig cell mitochondrial membrane potential and reduced StAR phosphorylation; NR supplementation in aging rodent models restores Leydig cell mitochondrial function and testosterone output. The PGC-1α pathway is the critical downstream link — SIRT1-mediated deacetylation of PGC-1α drives mitochondrial biogenesis in Leydig cells and hypothalamic neurons, potentially partially reversing both peripheral steroidogenic capacity and central GnRH pulsatility deficits. Combining NR with resveratrol (a SIRT1 allosteric activator) has demonstrated synergistic effects on NAD+ utilization in some human studies.